2023 SABCS Highlights

 

Review presentations on research findings presented by Dana-Farber physician-scientists at this year's San Antonio Breast Cancer Symposium (SABCS), held on December 5-9 in San Antonio, Texas. SABCS is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.

---

Video

Heather Parsons, MD, MPH Discusses Liquid Biopsy

Dana-Farber's Heather Parsons, MD, MPH, discusses a new study showing liquid biopsy could reliably determine whether a patient's breast cancer is HER2-positive or --negative.

Heather A. Parsons, MD, MPH

Medical Oncology

---

Video

Paolo Tarantino, MD Discusses RELIEVE Study

Dana-Farber's Paolo Tarantino, MD, presented results from the RELIEVE study showing patients with metastatic breast cancer receiving trastuzumab deruxtecan fared best if they had HER2+ disease or stable HER2-low disease.

---

Video

Kate Dibble, PhD Discusses Ovarian Function Suppression

Dana-Farber's Heather Parsons, MD, MPH, discusses a new study showing liquid biopsy could reliably determine whether a patient's breast cancer is HER2-positive or --negative.

 

Press Releases

Potentially targetable fusion RNAs may be more common in metastatic breast cancer than previously realized

Immunotherapy plus standard therapy can increase progression-free survival in patients with HER2+ metastatic breast cancer

Risk that metastatic breast cancer will spread to the brain varies with subtype of the disease

 

 Additional Resources

Dana-Farber Researchers to Present Findings at 2023 San Antonio Breast Cancer Symposium

Breast Cancer Treatment Guidelines developed by Dana-Farber on how to best utilize certain newly approved treatments

Listen to Unraveled, Dana-Farber’s podcast exploring the mysteries of the science of cancer